Nucleus Genomics Criticism: Embryo Testing Concerns
- Nucleus Genomics, a genetic testing startup, is facing criticism after announcing its Nucleus Embryo service.
- The company's announcement, made via social media, stated that Nucleus adds a new tool to the commitment every parent makes to give their children more than they had.
- While genetic testing of embryos is already used to screen for conditions like Down syndrome or cystic fibrosis,nucleus Genomics uses "polygenic scores" to determine the likelihood of complex...
News directory 3 reports on the controversy surrounding Nucleus Genomics‘ embryo testing service. this innovative service promises parents the ability to select for traits like IQ, height, and eye color, sparking widespread debate. critics immediately questioned the company’s use of polygenic scores, which experts say are unreliable for predicting individual outcomes. The announcement has ignited a firestorm of ethical concerns about “designer babies” and the future of genetic engineering. Despite the controversy, Nucleus Genomics defends its methodology, pointing to previous studies. Though, experts question the reliability of these scores in individual cases. What are the potential ramifications of this technology? Discover what’s next as we examine the implications of embryo genetic testing.
Nucleus Genomics’ Embryo Test Sparks Designer Baby Debate
Updated June 06, 2025
Nucleus Genomics, a genetic testing startup, is facing criticism after announcing its Nucleus Embryo service. The company, founded by Kian Sadeghi, claims the service can screen in vitro fertilization embryos for a range of traits, including appearance and even intelligence.This has ignited a debate about the ethics and accuracy of using genetic testing for embryo selection.
The company’s announcement, made via social media, stated that Nucleus adds a new tool to the commitment every parent makes to give their children more than they had. The service purports to assess embryos for sex, height, hair and eye color, as well as complex health attributes like anxiety and ADHD, in addition to screening for specific disease-related genes.
While genetic testing of embryos is already used to screen for conditions like Down syndrome or cystic fibrosis,nucleus Genomics uses “polygenic scores” to determine the likelihood of complex traits. The National Human Genome Research Institute notes that polygenic scores are primarily useful for assessing risk within populations, not for predicting individual outcomes. The institute also states that polygenic risk scores are not yet routinely used by health professionals because there are no guidelines for practice and researchers are still improving how these scores are generated.
A spokesperson for Nucleus Genomics defended the company’s methodology, citing a 2018 study that validated methods for predicting the risk of diseases such as coronary artery disease and Type 2 diabetes.The company argues that its testing can help individuals make informed lifestyle and therapeutic decisions.
The announcement of Nucleus Embryo has drawn significant attention, with many expressing skepticism and concern. One venture capitalist commented on social media,expressing unease about the implications of the technology.
Nucleus Genomics has faced controversy before, particularly after launching Nucleus IQ, a product that claimed to assess a person’s genetic predisposition for intelligence. Critics have called the product “bad science and big business.”
the Wall Street Journal reports that Nucleus genomics is partnering with Genomic prediction, which works with IVF clinics. While many parents request intelligence tests, Genomic Prediction does not provide that service. Parents can voluntarily upload genetic data data to Nucleus if they want to pursue it.
Not that long ago IVF-1 sparked fear and the stigma of test tube babies. What was once controversial is now an everyday practice. The same is true with genetic optimization. The technology is now here and it’s here to stay.
What’s next
As the debate surrounding Nucleus embryo continues, the focus will likely shift to regulatory oversight and ethical guidelines for genetic testing and embryo selection. The long-term implications of using polygenic scores to predict complex traits in individuals also warrant further research and discussion.